↓ Skip to main content

Loss of Programmed cell death 4 (Pdcd4) associates with the progression of ovarian cancer

Overview of attention for article published in Molecular Cancer, September 2009
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

googleplus
1 Google+ user

Citations

dimensions_citation
71 Dimensions

Readers on

mendeley
28 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Loss of Programmed cell death 4 (Pdcd4) associates with the progression of ovarian cancer
Published in
Molecular Cancer, September 2009
DOI 10.1186/1476-4598-8-70
Pubmed ID
Authors

Na Wei, Stephanie S Liu, Thomas HY Leung, Kar F Tam, Xiao Y Liao, Annie NY Cheung, Karen KL Chan, Hextan YS Ngan

Abstract

Programmed cell death 4 (Pdcd4) is a novel tumour suppressor and originally identified as a neoplastic transformation inhibitor. The aim of this study was to investigate the expression, prognostic significance and potential function of Pdcd4 in ovarian cancer.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 28 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Canada 1 4%
Unknown 27 96%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 7 25%
Researcher 4 14%
Student > Doctoral Student 3 11%
Other 3 11%
Student > Bachelor 2 7%
Other 4 14%
Unknown 5 18%
Readers by discipline Count As %
Agricultural and Biological Sciences 7 25%
Biochemistry, Genetics and Molecular Biology 5 18%
Medicine and Dentistry 4 14%
Materials Science 2 7%
Psychology 1 4%
Other 3 11%
Unknown 6 21%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 September 2013.
All research outputs
#15,280,625
of 22,723,682 outputs
Outputs from Molecular Cancer
#1,040
of 1,715 outputs
Outputs of similar age
#76,320
of 91,401 outputs
Outputs of similar age from Molecular Cancer
#6
of 9 outputs
Altmetric has tracked 22,723,682 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,715 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.7. This one is in the 30th percentile – i.e., 30% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 91,401 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 9th percentile – i.e., 9% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one. This one has scored higher than 3 of them.